Fudan University
🇨🇳China
- Country
- 🇨🇳China
- Ownership
- Private
- Established
- 1905-01-01
- Employees
- 1K
- Market Cap
- -
- Website
- http://www.fudan.edu.cn
ARX788 in HER2-positive Breast Cancer Patients With Brain Metastases
Phase 2
- Conditions
- HER2-positive, Metastatic Breast Cancer
- Interventions
- Drug: ARX788
- First Posted Date
- 2021-08-24
- Last Posted Date
- 2022-06-01
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 32
- Registration Number
- NCT05018702
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, China
ARX788 in Breast Cancer With Low Expression of HER2
Phase 2
- Conditions
- Breast Cancer With Low Expression of HER2
- Interventions
- Drug: ARX788
- First Posted Date
- 2021-08-24
- Last Posted Date
- 2022-04-25
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 54
- Registration Number
- NCT05018676
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, China
Health Benefits of Air Purifiers in Primary School Students
Not Applicable
- Conditions
- Cardiopulmonary FunctionChild
- Interventions
- Behavioral: Air purifier and fresh air ventilation systems with high-efficiency particulate air (HEPA) filtersBehavioral: Air purifier and fresh air ventilation systems without high-efficiency particulate air (HEPA) filters
- First Posted Date
- 2021-08-23
- Last Posted Date
- 2022-03-16
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 110
- Registration Number
- NCT05016271
- Locations
- 🇨🇳
Department of Environmental Health, School of Public Health, Fudan University, Shanghai, Shanghai, China
Lenvatinib Plus Sintilimab in Patients With Immune Checkpoint Inhibitor Previously Treated Advanced Liver Cancer
Phase 2
Recruiting
- Conditions
- Intrahepatic Cholangiocarcinoma
- Interventions
- First Posted Date
- 2021-08-18
- Last Posted Date
- 2023-09-13
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 25
- Registration Number
- NCT05010681
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
Cryoablation Combined With Sintilimab Plus Lenvatinib in Patients With Advanced Intrahepatic Cholangiocarcinoma
Phase 2
Recruiting
- Conditions
- Intrahepatic Cholangiocarcinoma
- Interventions
- First Posted Date
- 2021-08-18
- Last Posted Date
- 2023-09-13
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 25
- Registration Number
- NCT05010668
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, China
Study of Adjuvant Chemotherapy With or Without PD-1 Inhibitors and Chemoradiotherapy in Resected pN3 Gastric (G) or GEJ Adenocarcinoma
Phase 3
Recruiting
- Conditions
- Gastric Cancer
- Interventions
- Drug: PD-1 inhibitorDrug: OxaliplatinDrug: CapecitabineDrug: Tegafur-gimeracil-oteracil potassiumDrug: 5-FURadiation: RadiotherapyDrug: Chemotherapy
- First Posted Date
- 2021-08-10
- Last Posted Date
- 2021-08-10
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 433
- Registration Number
- NCT04997837
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
Tislelizumab in the Systematic Treatment of Advanced Hepatocellular Carcinoma
- Conditions
- Hepatocellular Carcinoma
- Interventions
- First Posted Date
- 2021-08-09
- Last Posted Date
- 2021-08-09
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 40
- Registration Number
- NCT04996459
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, China
ALPPS Combined With Tislelizumab in Liver Malignancy
- First Posted Date
- 2021-08-09
- Last Posted Date
- 2021-08-09
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 20
- Registration Number
- NCT04996446
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, China
Long-term Survivorship of Discharged Patients With Malignant Tumor Based on Single-institutional Cancer Registry
Recruiting
- Conditions
- SurvivalSurgeryRadiotherapyDrug TherapyNeoplasms
- Interventions
- Procedure: hospitalization
- First Posted Date
- 2021-08-09
- Last Posted Date
- 2021-08-09
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 500000
- Registration Number
- NCT04996732
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, China
Induction Chemotherapy and Toripalimab for Larynx Preservation in Resectable Laryngeal/Hypopharyngeal Carcinoma
Phase 2
Recruiting
- Conditions
- Laryngeal CancerHypopharynx CancerLaryngeal Neoplasms
- Interventions
- Drug: chemotherapy TP regimen combined with Toripalimab
- First Posted Date
- 2021-08-06
- Last Posted Date
- 2022-01-18
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 42
- Registration Number
- NCT04995120
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
© Copyright 2025. All Rights Reserved by MedPath